June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Evaluation of geographic atrophy secondary to age-related macular degeneration in clinical practice: analysis of the American Academy of Ophthalmology IRIS® Registry
Author Affiliations & Notes
  • M. Ali Khan
    Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
  • Ehsan Rahimy
    Palo Alto Medical Foundation, Palo Alto, California, United States
  • Ray Hsieh
    Verana Health, San Francisco, California, United States
  • Ramiro Ribiero
    Apellis Pharmaceuticals Inc, Crestwood, Kentucky, United States
  • Allen Ho
    Wills Eye Health System, Philadelphia, Pennsylvania, United States
  • Nancy M Holekamp
    Pepose Vision Institute, Chesterfield, Missouri, United States
  • Footnotes
    Commercial Relationships   M. Ali Khan, Allergan (C), Apellis (C), Genetech (C), Regeneron (F); Ehsan Rahimy, Allergan (C), Apellis (C), Eyepoint (C), Genentech (C), Google (C), Regeneron (C); Ray Hsieh, None; Ramiro Ribiero, Apellis (E); Allen Ho, Adverum (C), Aerie (C), AGTC (C), Alcon Laboratories Inc (C), Aledyra (C), Allergan (C), Apellis (C), Asclepix (C), Beaver-Visitec International Inc (C), Chengdu Kanghong Biotechnology (C), Genetech (C), Graybug (C), Gyroscope (P), Gyroscope (C), Iridex (C), Iveric (C), Johnson and Johnson (C), Lineage (C), MeriaGtx (C), Notal (C), Ocular Therapeutics (C), ONL (C), Optovue Inc (C), Regeneron Pharmaceuticals (C), RegenXBio (C); Nancy Holekamp, Acucela (C), Allergan (C), Apellis (C), Bayer (C), Clearside Biosciences (C), Gemini (C), Gemini (I), Genentech (C), Genentech (I), Gyroscope (C), Gyroscope (I), Katalyst Surgical (C), Katalyst Surgical (I), Lineage (C), Nacuity (C), Notal Vision (C), Notal Vision (I), Novartis (C), Polyactive (C), Regeneron (C), Regeneron (I), Spark Therapeutics (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 166. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Ali Khan, Ehsan Rahimy, Ray Hsieh, Ramiro Ribiero, Allen Ho, Nancy M Holekamp; Evaluation of geographic atrophy secondary to age-related macular degeneration in clinical practice: analysis of the American Academy of Ophthalmology IRIS® Registry. Invest. Ophthalmol. Vis. Sci. 2021;62(8):166.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To study patients with geographic atrophy (GA) across clinical practices in the United States and evaluate clinical characteristics and disease progression in patients with GA.

Methods : Retrospective analysis was conducted of patients with ICD-10 codes for GA (extrafoveal or foveal) in ≥1 eye from 2016 to 2017 with ≥2 years follow-up. Neovascular AMD in the study eye before GA diagnosis was exclusionary. Presenting clinical characteristics, visual acuity (VA) change, and disease progression through 24 months were analyzed.

Results : A total of 256,635 patients were identified, of which 69,441 were eligible for inclusion. Of these, 44,120 (64%) had bilateral GA (GA:GA) and 25,321 (36%) had CNV in the fellow eye (GA:nAMD). Cohorts were balanced for age, gender, and race. In the GA:GA cohort, study eyes with extrafoveal GA had better VA at index (mean 67 letters) compared to those with foveal GA (mean 59 letters). However, over 2 years, changes in VA were similar for both the extrafoveal and foveal lesion groups with a difference of -6.8 and -6.6 mean letters, respectively. Also in this cohort, 16.7% of study eyes progressed from extrafoveal to foveal GA over a median time of 66 weeks; 11.4% of the extrafoveal study eyes and 10.2% of foveal study eyes progressed to nAMD over a median time of 74 and 66 weeks, respectively. In the GA:nAMD cohort, changes in VA values at index and after 2 years were similar to those seen in the GA:GA group. However, patients with fellow-eye nAMD progressed more often to study eye nAMD in both the extrafoveal (29.3%) and foveal (26.0%) lesion categories, over a median time of 63 and 60 weeks, respectively. Additionally, 12.5% of study eyes in the GA:nAMD cohort progressed from extrafoveal to foveal GA over a median of 61 weeks.

Conclusions : This analysis confirms that GA is a prevalent and progressive disease with deteriorating impact on vision.

This is a 2021 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.